IL10 and colitis: However, the application of IL-10 for UC treatment is hindered by its short half-life and insufficient mucosal penetration.45 Increasing evidence has shown that the transfer of IL-10-producing Bregs may be a strategy to alleviate the severity of UC in different models.6, 27, 46–48 Oral administration of DSS solution to mice is widely used to mimic human UC because DSS-induced murine colitis shares similar pathological features to the UC observed in patients.27 In IL-10-GFP-reporter mice administered 3% DSS, we observed a reduction in the number of IL-10-secreting B cells in mLNs.